New Market Report: EpiCast Report: Generalized Anxiety Disorder - Epidemiology Forecast to 2024

From: Fast Market Research, Inc.
Published: Tue Dec 01 2015

GAD is a common mental illness that is characterized by persistent and unrelenting worrying about everyday things such as personal finances, health, family, and work. GAD can be accompanied by one or all of the following physical symptoms: headache, fatigue, restlessness, edginess, and increased irritability. GAD is only diagnosed if the patient's worrying and anxiety present most days out of a week for at least six months in combination with one or more of the physical symptoms. The diagnosis of GAD must also be shown not to be directly related to any substance abuse disorder or general medical condition; it must not occur exclusively during an episodic mood disorder, psychotic disorder, or pervasive developmental disorder.

GlobalData epidemiologists forecast that the 12-month total prevalent cases of GAD in the 8MM will grow by 4.8% from 13,688,954 cases in 2014 to 14,349,464 in 2024 and lifetime total prevalence will grow by 4.8% from 24,594,259 cases in 2014 to 25,770,599 in 2024. GlobalData epidemiologists predict that GAD will affect more women than men with 69.35% of 12-month GAD and 66.04% of lifetime GAD found in women in 2014. GlobalData epidemiologists forecast that the prevalence of 12-month and lifetime GAD peaks in the age group 50-59 years, which contributed 23.57% of 12-month GAD and 23.54% of lifetime GAD in the 8MM in 2014.

Full Report Details at

GlobalData's epidemiological analysis provides a country-specific forecast for the diagnosed prevalent cases of GAD in the 8MM during 2014-2024. GlobalData's epidemiological forecast for the 12-month and lifetime total prevalent cases of GAD in the 8MM is supported by epidemiological data from country-specific studies, when available, which are nationally representative of the entire population of the respective market. This forecast is further strengthened by the use of uniform diagnostic criteria and methodology across each study that was included in the forecast. All countries for which data was found used the DSM-IV diagnostic criteria as well as the CIDI to estimate the total prevalence of GAD in each country. Each study used also presented a total prevalence rather than diagnosed, which gives a better estimate of the true burden of the disease as it will catch the undiagnosed cases of the disease.

Report Scopet

* The Generalized Anxiety Disorder (GAD) EpiCast Report provides an overview of the risk factors, comorbidities, and global trends for GAD in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and Canada). It includes a 10-year epidemiological forecast of the one-year and lifetime prevalent cases of GAD segmented by sex, and age (in five-year increments beginning at 18 years and ending at =85 years) in these markets.
* The GAD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- EpiCast Report: Hemophilia - Epidemiology Forecast to 2024
- EpiCast Report: Growth Hormone Deficiency - Epidemiology Forecast to 2024
- EpiCast Report: Ankylosing Spondylitis - Epidemiology Forecast to 2024
- EpiCast Report: Fabry Disease - Epidemiology Forecast to 2024
- EpiCast Report: Gastric Cancer - Epidemiology Forecast to 2024

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email:
Contact Phone: 1-413-485-7001

Visit website »